NASDAQ:CNTN Hillstream Biopharma (CNTN) Stock Price, News & Analysis $2.22 -0.13 (-5.53%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC FilingsShort Interest About Hillstream Biopharma Stock (NASDAQ:CNTN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hillstream Biopharma alerts:Sign Up Key Stats Today's Range$2.20▼$2.3650-Day Range$1.85▼$3.2352-Week Range$1.75▼$7.25Volume516,292 shsAverage Volume646,910 shsMarket Capitalization$176.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey. Read More Hillstream Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreCNTN MarketRank™: Hillstream Biopharma scored higher than 9% of companies evaluated by MarketBeat, and ranked 832nd out of 851 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingHillstream Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageHillstream Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Hillstream Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hillstream Biopharma is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hillstream Biopharma is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHillstream Biopharma has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.15% of the float of Hillstream Biopharma has been sold short.Short Interest Ratio / Days to CoverHillstream Biopharma has a short interest ratio ("days to cover") of 13.78, which indicates bearish sentiment.Change versus previous monthShort interest in Hillstream Biopharma has recently decreased by 8.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHillstream Biopharma does not currently pay a dividend.Dividend GrowthHillstream Biopharma does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentHillstream Biopharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Finance companies.News Coverage This WeekMarketBeat has tracked 1 news article for Hillstream Biopharma this week, compared to 1 article on an average week.Search Interest3 people have searched for CNTN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Hillstream Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hillstream Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders3.34% of the stock of Hillstream Biopharma is held by insiders.Percentage Held by Institutions1.16% of the stock of Hillstream Biopharma is held by institutions.Read more about Hillstream Biopharma's insider trading history. Receive CNTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTN Stock News HeadlinesHead to Head Contrast: Hillstream Biopharma (NASDAQ:CNTN) vs. CNFinance (NYSE:CNF)August 23, 2026 | americanbankingnews.comHillstream Biopharma (NASDAQ:CNTN) Upgraded by Wall Street Zen to Hold RatingAugust 22, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 30 at 1:00 AM | Porter & Company (Ad)Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational ResultsAugust 14, 2026 | prnewswire.comCanton Strategic: Highly Intriguing Blockchain Treasury With Tangible RisksAugust 6, 2026 | seekingalpha.comThree New Directors Elected to the Board of Canton Strategic Holdings, Inc.July 28, 2026 | prnewswire.comCanton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLCJuly 23, 2026 | prnewswire.comCanton Strategic Holdings, Inc. Delivers Second Quarter Canton Network Ecosystem UpdateJuly 17, 2026 | prnewswire.comSee More Headlines CNTN Stock Analysis - Frequently Asked Questions How have CNTN shares performed this year? Hillstream Biopharma's stock was trading at $4.66 on March 10, 2026. Since then, CNTN stock has decreased by 52.4% and is now trading at $2.22. How do I buy shares of Hillstream Biopharma? Shares of CNTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CNTN's financial health is in the Yellow zone, according to TradeSmith. CNTN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Financial Services Sub-IndustryMulti-Sector Holdings Current SymbolNASDAQ:CNTN CIK1861657 Webhillstreambio.com Phone(302) 743-2995FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.92 million Net MarginsN/A Pretax Margin-7,641.51% Return on Equity-20.06% Return on Assets-15.90% Debt Debt-to-Equity RatioN/A Current Ratio15.70 Quick Ratio15.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.71 per share Price / Book0.39Miscellaneous Outstanding Shares79,680,000Free Float77,020,000Market Cap$176.89 million OptionableN/A Beta1.45 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CNTN) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhy Boston Ships In Natural Gas It Already Has at HomeA tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...Porter & Company | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHe called Apple then saw 12,000%+ gains. Now he's pointing at THIS.In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...Eagle Publishing | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
